Xenon Pharmaceuticals
About:
Xenon Pharmaceuticals operates as a neurology-focused biopharmaceutical company.
Website: http://www.xenon-pharma.com
Twitter/X: XenonPharma
Top Investors: Takeda, New Enterprise Associates, Neurocrine Biosciences, InterWest Partners, Novo Ventures
Description:
Xenon Pharmaceuticals is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as Extreme Genetics. Our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits or phenotypes. They apply their expertise to predict which phenotypes are caused by single-gene defects. By identifying and characterizing the single-gene defects responsible for such severe phenotypes, they gain valuable insights into their function in human biology and their potential as drug targets. Given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, they are developing proprietary product candidates to treat both orphans as well as more prevalent diseases
$1.29B
$1M to $10M
Burnaby, British Columbia, Canada
1996-01-01
investors(AT)xenon-pharma.com
Simon Pimstone
101-250
2023-11-29
Public
© 2025 bioDAO.ai